scholarly article | Q13442814 |
P356 | DOI | 10.1007/BF00686555 |
P698 | PubMed publication ID | 7805184 |
P2093 | author name string | J P Guastalla | |
Y Merrouche | |||
G Catimel | |||
M Clavel | |||
A Dumortier | |||
M Foy | |||
M K Alakl | |||
N Le Bail | |||
R Coquard | |||
P2860 | cites work | Clinical trials in cancer chemotherapy | Q39635134 |
Antitumor activity and mechanism of action of the marine compound girodazole | Q44717791 | ||
P433 | issue | 3 | |
P304 | page(s) | 246-248 | |
P577 | publication date | 1995-01-01 | |
P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
P1476 | title | Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors | |
P478 | volume | 35 |
Q37873742 | Biosynthesis, asymmetric synthesis, and pharmacology, including cellular targets, of the pyrrole-2-aminoimidazole marine alkaloids |
Q33519074 | Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. |
Q26753021 | Marine Natural Products from New Caledonia--A Review |
Q73668726 | Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials |
Q35211600 | Unbiased screening of marine sponge extracts for anti-inflammatory agents combined with chemical genomics identifies girolline as an inhibitor of protein synthesis |
Search more.